EG24052A - Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol - Google Patents

Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol

Info

Publication number
EG24052A
EG24052A EG23399A EG23399A EG24052A EG 24052 A EG24052 A EG 24052A EG 23399 A EG23399 A EG 23399A EG 23399 A EG23399 A EG 23399A EG 24052 A EG24052 A EG 24052A
Authority
EG
Egypt
Prior art keywords
piperidinemethapnol
demethoxyphenyl
fluorophenyl
ethyl
preparation
Prior art date
Application number
EG23399A
Other languages
English (en)
Inventor
Alan G Bina
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of EG24052A publication Critical patent/EG24052A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EG23399A 1998-03-13 1999-03-10 Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol EG24052A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4225198A 1998-03-13 1998-03-13
US25071899A 1999-02-16 1999-02-16

Publications (1)

Publication Number Publication Date
EG24052A true EG24052A (en) 2008-04-13

Family

ID=26719032

Family Applications (1)

Application Number Title Priority Date Filing Date
EG23399A EG24052A (en) 1998-03-13 1999-03-10 Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol

Country Status (25)

Country Link
EP (3) EP1192134B1 (ja)
JP (2) JP4511723B2 (ja)
KR (7) KR100591640B1 (ja)
CN (1) CN100436415C (ja)
AR (1) AR015540A1 (ja)
AT (1) ATE373639T1 (ja)
AU (1) AU755436B2 (ja)
BR (1) BR9909260A (ja)
CA (1) CA2322501C (ja)
CY (1) CY1107104T1 (ja)
DE (1) DE69937162T2 (ja)
DK (1) DK1192134T3 (ja)
DZ (1) DZ2742A1 (ja)
EG (1) EG24052A (ja)
ES (1) ES2294838T3 (ja)
HK (1) HK1042484B (ja)
HU (1) HUP0400889A3 (ja)
IL (3) IL138307A0 (ja)
MA (1) MA25515A1 (ja)
NO (1) NO317981B1 (ja)
NZ (1) NZ506807A (ja)
PT (1) PT1192134E (ja)
TN (1) TNSN99035A1 (ja)
TW (1) TWI249526B (ja)
WO (1) WO1999046245A2 (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713627B2 (en) * 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
DE19934432A1 (de) 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
DE102004010132A1 (de) 2004-02-27 2005-09-15 Merck Patent Gmbh Piperidinderivate
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
US8964338B2 (en) 2012-01-11 2015-02-24 Emerson Climate Technologies, Inc. System and method for compressor motor protection
WO2014144446A1 (en) 2013-03-15 2014-09-18 Emerson Electric Co. Hvac system remote monitoring and diagnosis
CN112358398A (zh) * 2020-11-19 2021-02-12 山东新华制药股份有限公司 D-(+)-二对甲苯甲酰酒石酸的回收制备方法
CN116082705B (zh) * 2022-12-05 2023-09-12 苏州易昇光学材料股份有限公司 一种抗黄变自修复凝胶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260623A (en) * 1979-11-26 1981-04-07 Warner-Lambert Company Hexahydro-1-arylspiro(3H-oxazolo(3,4-A)pyridine-3,4'-piperidene) antidepressants, pharmaceutical compositions thereof and method of use thereof
US5169096A (en) * 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
CA1280421C (en) * 1985-07-02 1991-02-19 Albert A. Carr 1,4-disubstituted piperidinyl derivatives
DE69105501T2 (de) * 1990-06-01 1995-04-13 Merrell Dow Pharma (+)-alpha-(2,3 dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinmethanol.
WO1991018603A1 (en) * 1990-06-07 1991-12-12 Merrell Dow Pharmaceuticals Inc. 1-pyperidinyl alkanoylarylsulfonamide derivatives
US5477029A (en) * 1994-01-28 1995-12-19 Skutt Ceramic Products, Inc. Kiln with hinged control panel
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Also Published As

Publication number Publication date
KR100591642B1 (ko) 2006-06-20
KR20010041819A (ko) 2001-05-25
JP2002506059A (ja) 2002-02-26
CN1300280A (zh) 2001-06-20
DE69937162T2 (de) 2008-06-12
KR100591641B1 (ko) 2006-06-20
CY1107104T1 (el) 2012-01-25
IL175983A0 (en) 2006-10-05
EP1736469A2 (en) 2006-12-27
KR100586327B1 (ko) 2006-06-08
MA25515A1 (fr) 2002-10-01
WO1999046245A3 (en) 1999-10-21
IL138307A (en) 2006-09-05
JP2010143925A (ja) 2010-07-01
CA2322501A1 (en) 1999-09-16
KR20060002039A (ko) 2006-01-06
AU755436B2 (en) 2002-12-12
TNSN99035A1 (fr) 2005-11-10
DK1192134T3 (da) 2007-11-26
KR20060002036A (ko) 2006-01-06
HUP0400889A2 (hu) 2004-08-30
HUP0400889A3 (en) 2010-08-30
NO20004545L (no) 2000-11-13
ATE373639T1 (de) 2007-10-15
DZ2742A1 (fr) 2003-09-08
CN100436415C (zh) 2008-11-26
EP1734037A3 (en) 2010-06-16
HK1042484B (zh) 2008-05-02
KR100591640B1 (ko) 2006-06-20
JP4511723B2 (ja) 2010-07-28
KR20060002038A (ko) 2006-01-06
WO1999046245A2 (en) 1999-09-16
NZ506807A (en) 2003-03-28
CA2322501C (en) 2006-05-09
EP1734037A2 (en) 2006-12-20
KR20060002034A (ko) 2006-01-06
HK1042484A1 (en) 2002-08-16
KR20060002035A (ko) 2006-01-06
EP1192134A2 (en) 2002-04-03
NO317981B1 (no) 2005-01-17
AR015540A1 (es) 2001-05-02
KR100591997B1 (ko) 2006-06-26
IL138307A0 (en) 2001-10-31
ES2294838T3 (es) 2008-04-01
KR100591643B1 (ko) 2006-06-20
KR20060002037A (ko) 2006-01-06
NO20004545D0 (no) 2000-09-12
PT1192134E (pt) 2007-11-13
EP1736469A3 (en) 2010-06-09
EP1192134B1 (en) 2007-09-19
KR100586328B1 (ko) 2006-06-08
TWI249526B (en) 2006-02-21
AU2998899A (en) 1999-09-27
BR9909260A (pt) 2000-11-21
DE69937162D1 (de) 2007-10-31

Similar Documents

Publication Publication Date Title
ZA977524B (en) Process for the preparation of bone cements comprising active compound.
HUP0001539A3 (en) 2-(1-iminoethylamino)ethyl-homocysteine, process for its preparation and pharmaceutical compositions containing the same
HUP0004388A3 (en) Process for the preparation of oxazolidinones, intermediates and preparation thereof
HUP0100779A3 (en) Novel derivatives of 3,3-diphenylpropylamines
HUP0004664A3 (en) Process for the preparation of acylated cyclic 1,3-dicarbonyl compounds
IL129906A0 (en) Process for the preparation of beta-isophorone
HUP0100640A3 (en) Process for the preparation of 1,4-dihydropyridines
EG24052A (en) Novel processes for the preparation of (r)-a (2,3-demethoxyphenyl-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethapnol
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
EP0692476A3 (de) Verbessertes Verfahren zur Herstellung von N,N'-Carbonyldiazolen, insbesondere N,N'-Carbonyldiimidazol
HUP0003452A3 (en) Process for the preparation of 1-aryl-3-cyclopropyl-1,3-propanediones
ZA982255B (en) Process for the preparation of arylmalonates.
AU6870500A (en) Process for the preparation of 2,3-dihydroazepine derivatives
ZA988397B (en) Process for the preparation of substituted 5,6-dihydro-2H-pyran-2-ones
GB2357758B (en) Process for the preparation of 1,1-cyclopropanedicarboxylic diesters
IL147830A0 (en) Process for the preparation of acylated 1,3-dicarbonyl compounds
EP0690053A3 (de) Verfahren zur Herstellung von 2,5-Dihydrofuran
IL141947A0 (en) Process for the preparation of 4,4'-dihalogen-o-hydroxydiphenyl compounds
HUP0000982A2 (en) Process for the preparation of 1,1-dioxo-penicillanic acid derivatives
HUP0102710A2 (hu) Új eljárás prosztaglandinvegyületek előállítására
PL344141A1 (en) Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides
HUP9902745A3 (en) Process for the preparation of benzylcarbazate
ZA9811238B (en) Process for the preparation of isopropyl-methyl-(2-(3-n-propoxyphenoxy)ethyl)amine
AU2905900A (en) Process for the preparation of 2,2,6,6-tetraalkylpiperidin-1-oxyl via 1,2,3,6-tetrahydro-2,2,6,6-tetraalkylpyridine
AU2188101A (en) 1,6,6-triazacyclohexane coordination compounds for the preparation of metal containing polymers